Robert Hofbauer

Robert Hofbauer is the Executive Director, Clinical Science at Acadia Pharmaceuticals Inc., responsible for leading the strategy and tactics for the pimavanserin autism program. With a background in neurological sciences and psychology, Robert has held various senior roles in clinical development at companies like Mitsubishi Tanabe Pharma Development America and Turing Pharmaceuticals AG. As a Principal Consultant at Surmount Pharma Consulting, Robert provides clinical development consulting services to the pharmaceutical and biotechnology industry. Throughout their career, Robert has demonstrated expertise in leading clinical trial operations, managing early development projects, and overseeing clinical development programs for orphan indications in CNS and infectious disease.